C0701a/501, an open-label extended-use study of oral CEP-701 [lestaurtinib] in patients with hematologic and non-hematologic malignancies who have completed a clinical study of CEP-701

Trial Profile

C0701a/501, an open-label extended-use study of oral CEP-701 [lestaurtinib] in patients with hematologic and non-hematologic malignancies who have completed a clinical study of CEP-701

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Lestaurtinib (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Cephalon
  • Most Recent Events

    • 15 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top